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Spinal Muscular Atrophy (SMA) is neuromuscular disorder that results in the devastating weakness and wasting of the voluntary muscles in the extremities of infants and children. 1 The disease is caused by the homozygotic loss of the survival-of-motoneuron-1 gene (SMN1) that encodes a protein crucial for small nuclear ribonucleic protein (snRNP) assembly and axonal transport. 2 The absence of SMN results in the loss of spinal cord motor-neurons with tragic outcomes, resulting in death in early infancy. Humans express a related gene, survival-of-motoneuron-2 (SMN2) that is generated through a duplication event and that differs from SMN1 by a silent C?T transition but that is otherwise almost identical to SMN1. The C?T transition (C280T) disrupts a splicing enhancer, which causes predominant skipping of exon 7, resulting in an unstable protein with a different C-terminus. 3 The near identity of the mRNA sequences of SMN1 and SMN2 with inclusion of exon 7 suggested that a therapy for SMA could be based on agents that promote exon 7 inclusion. 2 There is weak inclusion of exon 7 due to a splicing enhancer formed by three key splicing factors:
tra2-beta1, SRp30c and the heterogeneous nuclear ribonucleoprotein hnRNPG. 4, 5 Tra2-beta1 binds directly to protein phosphatase-1 (PP1), and the inhibition of the phosphatase by cantharidin and other PP1 inhibitors promote exon 7 inclusion in cell and mouse models 6 ( Fig. 1 ). We previously developed cantharidin and norcantharidin analogs that blocked PP1 and promoted exon 7 inclusion. 7 Consistent with other, known PP1 inhibitors, the cantharidin and norcantharidin derivatives lack selectivity for exon 7 inclusion because PP1 binds to an RNA recognition motif of several splicing factors where it regulates alternative splicing. 6, 8 Since PP1 has numerous regulatory partners, we sought to develop PP1 inhibitors linked at the 3 0 -position to a 2 0 -methoxyoligonucleotide that would complement the proximal intron 7 and selectively direct the inhibitor to PP1 associated with the spliceosome. Prior work by the McCluskey group 9-13 and others 7, 14 identified racemic monoamide derivatives of 3a,4,7,7a-hexahydro-4,7-epoxyisobenzofuran-1,3-dione, 11 commonly called norcantharidin (1), as potent PP1 inhibitors (Fig. 2) . The monoamides 2 produced from secondary amines displayed good PP1 inhibitory activity 10 relative to the corresponding monoamides 3 of primary amines that were prone to cyclize to the inactive imides 4 (Fig. 2) . Since we ultimately required a norcantharidin monoamide tethered to a 2 0 -methoxyoligonucleotide octamer 9 (Fig. 3) , we planned to utilize a polymer-based synthesis in which an unsymmetrical tether 5 with a secondary amino-terminus linked to a polymer through a terephthaloyl group and with a hydroxy terminus that was suitable for the elaboration of the 2 0 -methoxyoligonucleotide (Fig. 3) . Linkage of the tether through the commonly used N-phthalimidoyl group would not accommodate a secondary amine. Ammonolysis of 7 would cleave the linkage to the polymer and remove guanosine-protecting groups, and the attachment of the inhibitor to 8 would complete the synthesis of the inhibitortether-oligonucleotide 9. Central to these plans was the overarching need to determine if a norcantharidin monoamide tethered to a nucleotide would retain PP1 inhibitory activity.
Synthesis of an norcantharidin-tethered guanosine proceeded from the symmetrical 1,4-bis(2,2 0 -hydroxyethyl)benzene (10) and involved the protection of one hydroxyl group in 10 as a 4,4 0 -dimethoxytrityl (DMT) ether and the elaboration of the hydroxyl group at the other terminus in 11 to N-methylamino group (Fig. 4) .
The latter transformation involved conversion of 11 to the azide 13 via the tosylate 12; addition of ethyl chloroformate; and reduction 15 We tested norcantharidin derivatives using an in vivo minigene assay. 18 The monoamide 2a of norcantharidin and N-methylphenethylamine, which represented a portion of the tethered norcantharidin without a nucleotide, was added to HEK293 cells cotransfected with an SMN2-reporter minigene. 6 Because the monoamide 2a displayed activity, we synthesized the norcantharidin-tether-guanosine construct 20 (Fig. 4) and determined that 20 increased exon 7 inclusion in a concentration-dependent manner and increased exon inclusion by about 25% (Fig. 5A) with statistical significance at the 10-100 lM concentrations. As a control, the tether or 'linker', namely 2-(4-(2-(methylamino)ethyl)phenyl)ethan-1-ol, which connected the norcantharidin and guanosine, showed no effect on inclusion (Fig. 5B) .
In summary, methodology for the synthesis of a guanosinetethered norcantharidin was developed that could accommodate the synthesis of a norcantharidin-tether-oligonucleotide. Although the stage was now set for the synthesis of such a construct, the modest change in exon inclusion seen with 20 did not warrant the investment of effort in this undertaking.
